AMENDMENTS TO THE CLAIMS

1. (Currently Amended) An antifibrillogenic agent for inhibiting amyloidosis and/or for cytoprotection, which comprises a peptide of Formula I consisting of all [D]-amino acids, or a retro-isomer of a peptide of Formula I consisting of all [D]-amino acids ~~an isomer thereof, a retro or a retro-inverso isomer thereof or a peptidomimetic thereof~~:

Xaa_1-Xaa_2-Xaa_3-Xaa_4 (Formula I)

wherein,

Xaa_1 is selected from the group consisting of Lys and Xaa_5-Lys-;

Xaa_5 is selected from the group consisting of Lys, His-Gln-, His-His-Gln-, Val-His-His-Gln-, Glu-Val-His-His-Gln-, Asp-Asp-Asp-, and Gln-;

Xaa_2 is any amino acid;

Xaa_3 is Val; and

Xaa_4 is selected from the group consisting of Phe, Phe-NH_2, Phe-Phe, Phe-Phe-NH_2, Phe-Phe-Ala, Phe-Phe-Ala-NH_2, Phe-Phe-Ala-Gln, and Phe-Phe-Ala-Gln-NH_2;

~~wherein said peptide has at least one [D] amino acid residue,~~

~~with the proviso that Lys-Lys-Leu-Val-Phe-Phe-Ala is an all-[D] peptide~~.

2. (Original) The antifibrillogenic agent of claim 1, wherein Xaa_2 is a hydrophobic amino acid residue.

3. (Currently Amended) The antifibrillogenic agent of claim 1, wherein ~~the peptide of formula I has at least two [D]~~ Xaa_2 is an amino acid residue selected from the group consisting of Leu, Ile, Ala, Val, and Phe ~~residues~~.

4 and 5. (Canceled).

6. (Currently Amended) The antifibrillogenic agent of claim 1, wherein said retro-isomer is selected from the group consisting of: ~~the peptide of formula I is an all-[D] isomer peptide~~

Ala-Phe-Phe-Val-Leu-Lys (SEQ ID NO:5); and

Ala-Phe-Phe-Val-Leu-Lys-NH_2 (SEQ ID NO:13).

7. (Currently Amended) The antifibrillogenic agent of claim 1, wherein said peptide of Formula I is selected from the group consisting of:

Lys-Ile-Val-Phe-Phe-Ala	(SEQ ID NO:l);
Lys-Lys-Leu-Val-Phe-Phe-Ala	(SEQ ID NO:2);
Lys-Leu-Val-Phe-Phe-Ala	(SEQ ID NO:3);
Lys-Phe-Val-Phe-Phe-Ala	(SEQ ID NO:4);
~~Ala-Phe-Phe-Val-Leu-Lys~~	~~(SEQ ID NO:5);~~
Lys-Leu-Val-Phe	(SEQ ID NO:6);
Lys-Ala-Val-Phe-Phe-Ala	(SEQ ID NO:7);
Lys-Leu-Val-Phe-Phe	(SEQ ID NO:8);
Lys-Val-Val-Phe-Phe-Ala	(SEQ ID NO:9);
Lys-Ile-Val-Phe-Phe-Ala-NH_2	(SEQ ID NO:l0);
Lys-Leu-Val-Phe-Phe-Ala-NH_2	(SEQ ID NO:11);
Lys-Phe-Val-Phe-Phe-Ala-NH_2	(SEQ ID NO:12);
~~Ala-Phe-Phe-Val-Leu-Lys-NH_2~~	~~(SEQ ID NO:13);~~
Lys-Leu-Val-Phe-NH_2	(SEQ ID NO:14);
Lys-Ala-Val-Phe-Phe-Ala-NH_2	(SEQ ID NO:15);
Lys-Leu-Val-Phe-Phe-NH_2	(SEQ ID NO:16);
Lys-Val-Val-Phe-Phe-Ala-NH_2	(SEQ ID NO:17);
Lys-Leu-Val-Phe-Phe-Ala-Gln	(SEQ ID NO:l8);
Lys-Leu-Val-Phe-Phe-Ala-Gln-NH_2	(SEQ ID NO:19);
His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-NH_2	(SEQ ID NO:20);
~~His-His-Gln-Lys~~	~~(SEQ ID NO:23);~~ and
Gln-Lys-Leu-Val-Phe-Phe-NH_2	(SEQ ID NO:24).

8. (Currently Amended) The antifibrillogenic agent of claim 1, wherein the peptide of Formula ~~formula~~ I is a peptide of ~~as set forth in~~ SEQ ID NO:2.

9-19. (Canceled).

20. (Currently Amended) A composition for the treatment of amyloidosis disorders in a patient, which comprises a therapeutically effective amount of a peptide of Formula I as defined in claim 1 or a retro-isomer thereof, and ~~in association with~~ a pharmaceutically acceptable carrier.

21. (Currently Amended) A composition for the treatment of amyloidosis disorders in a patient, which comprises a therapeutically effective amount of an antifibrillogenic agent as defined in claim 1, and ~~in association with~~ a pharmaceutically acceptable carrier.

22-31. (Canceled).

32. (Currently Amended) A composition for inhibiting amyloidosis and/or for cytoprotection, which comprises a therapeutically effective amount of a peptide as defined in claim 1 or a retro-isomer thereof, and ~~31 in association with~~ a pharmaceutically acceptable carrier.

33-36. (Canceled).

37. (Currently Amended) The antifibrillogenic agent of claim 1, wherein the peptide of Formula ~~formula~~ I is a peptide of ~~as set forth in~~ SEQ ID NO:3.

38. (Canceled).

39. (New) The composition of claim 20, wherein said amyloidosis disorder is Alzheimer's disease.

40. (New) The composition of claim 21, wherein said amyloidosis disorder is Alzheimer's disease.

41. (New) An antifibrillogenic agent for inhibiting amyloidosis and/or for cytoprotection, which comprises a peptide having an amino acid sequence selected from the group consisting of:

Lys-Ile-Val-Phe-Phe-Ala	(SEQ ID NO:l);
Lys-Lys-Leu-Val-Phe-Phe-Ala	(SEQ ID NO:2);
Lys-Leu-Val-Phe-Phe-Ala	(SEQ ID NO:3);
Lys-Phe-Val-Phe-Phe-Ala	(SEQ ID NO:4);
Ala-Phe-Phe-Val-Leu-Lys	(SEQ ID NO:5);
Lys-Leu-Val-Phe	(SEQ ID NO:6);
Lys-Ala-Val-Phe-Phe-Ala	(SEQ ID NO:7);
Lys-Leu-Val-Phe-Phe	(SEQ ID NO:8);
Lys-Val-Val-Phe-Phe-Ala	(SEQ ID NO:9);
Lys-Ile-Val-Phe-Phe-Ala-NH_2	(SEQ ID NO:l0);
Lys-Leu-Val-Phe-Phe-Ala-NH_2	(SEQ ID NO:11);
Lys-Phe-Val-Phe-Phe-Ala-NH_2	(SEQ ID NO:12);
Ala-Phe-Phe-Val-Leu-Lys-NH_2	(SEQ ID NO:13);
Lys-Leu-Val-Phe-NH_2	(SEQ ID NO:14);
Lys-Ala-Val-Phe-Phe-Ala-NH_2	(SEQ ID NO:15);
Lys-Leu-Val-Phe-Phe-NH_2	(SEQ ID NO:16);
Lys-Val-Val-Phe-Phe-Ala-NH_2	(SEQ ID NO:17);
Lys-Leu-Val-Phe-Phe-Ala-Gln	(SEQ ID NO:l8);
Lys-Leu-Val-Phe-Phe-Ala-Gln-NH_2	(SEQ ID NO:19);
His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-NH_2	(SEQ ID NO:20);
His-His-Gln-Lys	(SEQ ID NO:23); and
Gln-Lys-Leu-Val-Phe-Phe-NH_2	(SEQ ID NO:24);

wherein said amino acid sequence consists of all [D]-amino acids.

42. (New) An antifibrillogenic agent for inhibiting amyloidosis and/or for cytoprotection, which comprises the sequence of SEQ ID NO:2, wherein said sequence consists of all [D]-amino acids.